Hetero announces the launch of ‘Favivir’ (Favipiravir 200 mg) in India to treat mild to moderate Covid-19

Hyderabad, India; 29th July 2020: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of antiretroviral drugs, today announces the launch of generic Favipiravir in India under the brand name ‘Favivir.’Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI). 
 
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid 19 patient population, which usually sustains mild to moderate symptoms.
 
Hetero’s Favivir is priced at Rs. 59 per tablet and is marketed and distributed by Hetero Healthcare Limited. The product is available from today at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.
 
Backed by strong vertical integration capabilities, the drug is being manufactured at ourworld-class formulation facility in India, which has been approved by stringent global regulatory authorities such as USFDA and the EU, among others.